Fulcrum Therapeutics, Inc. (FULC)
$3.85+$0.00 (+0.00%) Today
Latest FULC Insider Trades
Kevin TangOpen-market purchase$415K
Kevin TangKevin TangKevin TangKevin TangKevin TangKevin Tang
Alan EzekowitzFulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 6 | 417,562 | $1.49M |
| Open-market sale | 1 | 18,000 | $66K |
| Grant or award | 8 | 256,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
22 Form 4 filings on record, the earliest from Nov 14, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Kevin Tang | Open-market purchase | Common Stock | 116,671 | $3.56 | $415K | |
| Kevin Tang | Open-market purchase | Common Stock | 50,945 | $3.52 | $179K | |
| Kevin Tang | Open-market purchase | Common Stock | 12,966 | $3.54 | $46K | |
| Kevin Tang | Open-market purchase | Common Stock | 53,651 | $3.56 | $191K | |
| Kevin Tang | Open-market purchase | Common Stock | 75,952 | $3.58 | $272K | |
| Kevin Tang | Open-market purchase | Common Stock | 107,377 | $3.56 | $382K | |
| Sonja Banks | Grant or award | Stock Option (right to buy) | 32,000 | $0.00 | - | |
| Katina Dorton | Grant or award | Stock Option (right to buy) | 32,000 | $0.00 | - | |
| Robert J. Gould | Grant or award | Stock Option (right to buy) | 32,000 | $0.00 | - | |
| Kate Haviland | Grant or award | Stock Option (right to buy) | 32,000 | $0.00 | - | |
| Rachel K. King | Grant or award | Stock Option (right to buy) | 32,000 | $0.00 | - | |
| James A. Geraghty | Grant or award | Stock Option (right to buy) | 32,000 | $0.00 | - | |
 Colin Hill | Grant or award | Stock Option (right to buy) | 32,000 | $0.00 | - | |
| Alan Ezekowitz | Grant or award | Stock Option (right to buy) | 32,000 | $0.00 | - | |
| Alan Ezekowitz | Open-market sale | Common Stock | 18,000 | $3.65 | $66K | |
| Joshua Lehrer-Graiwer | Grant or award | Stock Option (right to buy) | 64,000 | $0.00 | - | |
| Robert J. Gould | Open-market sale | Common Stock | 15,000 | $10.87 | $163K | |
 Alan A. Musso - Officer | Grant or award | Stock Option (right to buy) | 170,000 | $0.00 | - | |
| Curtis Gale Oltmans - Officer | Grant or award | Stock Option (right to buy) | 170,000 | $0.00 | - | |
| Greg Tourangeau - Officer | Grant or award | Stock Option (right to buy) | 57,000 | $0.00 | - | |
 Alex Sapir - Officer | Grant or award | Stock option - Right to Buy | 650,000 | $0.00 | - | |
| Robert J. Gould | Open-market sale | Common Stock | 15,000 | $11.87 | $178K | |
| Curtis Gale Oltmans - Officer | Open-market sale | Common Stock | 3,452 | $12.92 | $45K | |
| Robert J. Gould | Open-market sale | Common Stock | 15,000 | $11.03 | $165K | |
| James A. Geraghty | Grant or award | Stock Option (right to buy) | 36,000 | $0.00 | - | |
| Rachel K. King | Grant or award | Stock Option (right to buy) | 60,000 | $0.00 | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR |
Fulcrum Therapeutics, Inc. (FULC) had 11 insider filings in the last 90 days, with the most recent on 2026-07-21. The full record for FULC runs to 22 Form 4 filings, the earliest from 2024-11-14. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
6 insider purchases of FULC were filed in the last 90 days, totaling $1.49M.
1 insider sale of FULC was filed in the last 90 days, totaling $66K.
This page tracks FULC Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add FULC to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
